Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

Novartis (NVS) presented encouraging results from a pre-specified interim analysis of the phase III APPLAUSE-IgAN study of Fabhalta (iptacopan).Fabhalta, an oral, Factor B inhibitor of the alternative complement pathway, is already approved by the FDA for the treatment of adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria.Novartis is looking to expand the drug’s label for the treatment of immunoglobulin A nephropathy (IgAN), a heterogeneous, progressive, rare kidney disease.APPLAUSE-IgA ...